Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection

To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.

Key Inclusion Criteria:

• Participants chronically infected with hepatitis C virus (HCV) genotype 2 or 3
• No previous exposure to an interferon formulation (ie, interferon alfa, pegylated interferon alfa-2a ) or ribavirin
• Body mass index (BMI) of 18 to 35 kg/m^2, inclusive. BMI=weight (kg)/height (m)^2
• Males and females, 18 - 70 years of age

Key Exclusion Criteria:

• Liver transplant recipients
• Documented or suspected hepatocellular carcinoma
• Evidence of decompensated cirrhosis
• History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may participate
• Current or known history of cancer
• Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug
• Inability to tolerate oral medication
• Poor venous access
• Severe psychiatric disease
• History of chronic pulmonary disease
• History of cardiomyopathy, coronary artery disease (including angina), interventive procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant cardiac disease
• History of or current electrocardiogram findings indicative of cardiovascular instability
• Preexisting ophthalmologic disorders considered clinically significant on eye
• History of uncontrolled diabetes mellitus
• Any known contraindication to pegylated interferon alfa-2a or ribavirin not otherwise specified.
• Positive hepatitis B virus surface antigen, HIV-1 or HIV-2 Ab
• Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase, previous nonstructural protein 5A inhibitors)
• Exposure to any investigational drug or placebo